Cellectar Biosciences, Inc.
CLRB
$2.36
-$0.15-5.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.84M | -21.79M | -18.85M | -29.07M | -24.54M |
| Total Depreciation and Amortization | 47.40K | 213.70K | 232.80K | 249.10K | 259.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.04M | 1.59M | -7.27M | -4.35M | -16.08M |
| Change in Net Operating Assets | 1.18M | -3.13M | -3.80M | -1.40M | -3.24M |
| Cash from Operations | -18.58M | -23.12M | -29.69M | -34.58M | -43.60M |
| Capital Expenditure | -9.30K | -5.90K | -61.30K | -61.30K | -82.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -9.30K | -5.90K | -61.30K | -61.30K | -82.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.03M | 13.03M | 8.04M | 19.81M | 17.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.03M | 13.03M | 8.04M | 19.81M | 17.56M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.56M | -10.09M | -21.71M | -14.83M | -26.13M |